Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.40 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888782 | 0.92 | PANK3 (0.42) | MTORKDM4EL3MBTL1TRPV1GRM1 | |
| SCHEMBL3878569 | 0.92 | PIK3CD (0.42) | MTORKDM4EL3MBTL1GRM1PIK3CA | |
| SCHEMBL3877311 | 0.90 | TRPV1 (0.43) | MTORTRPV1GRM1PIK3CAALDH1A1 | |
| SCHEMBL3876031 | 0.90 | GRM1 (0.40) | MTORGRM1PIK3CAALDH1A1MAPT | |
| SCHEMBL3880046 | 0.89 | GRM1 (0.40) | MTORKDM4ETRPV1GRM1PIK3CA | |
| SCHEMBL3878243 | 0.89 | GRM1 (0.40) | MTORGRM1PIK3CAALDH1A1MAPT | |
| SCHEMBL3889177 | 0.89 | TRPV1 (0.51) | MTORTRPV1PIK3CA | |
| SCHEMBL3880084 | 0.89 | GRM1 (0.39) | MTORGRM1PIK3CAALDH1A1MAPT | |
| SCHEMBL3882209 | 0.88 | MTOR (0.45) | MTORKDM4EL3MBTL1TRPV1PIK3CA | |
| SCHEMBL3880985 | 0.88 | DGAT1 (0.41) | MTORGRM1PIK3CAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | MTOR 2949/4885KDM4E 3890/4885L3MBTL1 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.